Recommendation of the President – Keytruda (pembrolizumab)

On 25 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 96/2025 on the inclusion of the medicinal product Keytruda (pembrolizumab) in the drug program “Treatment of patients with urothelial cancer (ICD-10: C61, C65, C66, C67, C68)”

Publication in Public Information Bulletin (BIP) >>